Fresenius Medical Care Brings Peritoneal Dialysis and Home Hemodialysis Management into One Digital Platform

Fresenius Medical Care Brings Peritoneal Dialysis and Home Hemodialysis Management into One Digital Platform

(IN BRIEF) Fresenius Medical Care has launched kinexus worldwide as a unified digital platform designed to support home dialysis programs by combining remote therapy monitoring, prescription management, and supply-ordering workflows in one integrated system. The platform supports both peritoneal dialysis and home hemodialysis, enabling treatment data collected at home to be transmitted to clinics for review while allowing healthcare teams to manage and update prescriptions remotely. Built as a modular solution on the Huma Cloud Platform, kinexus is intended to simplify care coordination, improve operational efficiency, and support more personalized care for patients dialyzing at home. The launch is part of Fresenius Medical Care’s broader effort to expand connected kidney care solutions globally, with regional availability aligned with local regulatory and operational requirements. Fresenius Medical Care is showcasing kinexus at the European Renal Association Congress 2026 in Glasgow.

(PRESS RELEASE) BAD HOMBURG, 3-Jun-2026 — /EuropaWire/ — Fresenius Medical Care has introduced kinexus worldwide, a unified digital platform developed to support home dialysis programs by connecting remote therapy monitoring, prescription management, and operational workflows in one integrated system.

The global launch marks an important step in Fresenius Medical Care’s efforts to expand connected care for patients receiving dialysis at home. Designed for healthcare teams and patients, kinexus brings together digital capabilities for both peritoneal dialysis and home hemodialysis, enabling care providers to manage key aspects of home therapy through a single platform across the company’s global home dialysis portfolio.

Home dialysis programs require close coordination between patients, clinics, care teams, and supply operations. kinexus is designed to simplify this process by allowing treatment information collected in the patient’s home to be transmitted regularly to the clinic for review. This remote monitoring capability can help healthcare professionals stay more closely informed about therapy progress and support timely clinical decision-making.

The platform also supports remote prescription management, allowing healthcare teams to update and send prescriptions to patients without requiring unnecessary in-person steps. By helping care teams adapt therapy plans more efficiently, kinexus aims to support more personalized care while reducing administrative complexity in home dialysis programs.

In addition to therapy-related functions, kinexus includes integrated supply ordering for both peritoneal dialysis and home hemodialysis. This feature is intended to streamline operational workflows for clinics and care teams while making the treatment experience easier for patients managing dialysis at home.

Joe Turk, Chief Executive Officer of Care Enablement at Fresenius Medical Care, said kinexus reflects the company’s long-term commitment to home therapies and its focus on building the digital infrastructure needed to support modern home dialysis care. He noted that the unified platform connects therapy management with operational processes, creating a stronger digital foundation for the real-world needs of home dialysis programs.

Built as a modular solution on the Huma Cloud Platform, kinexus is designed to support current and future home dialysis capabilities within a consistent regulated digital framework. Its modular architecture enables Fresenius Medical Care to add further functions over time while maintaining a unified system for managing home therapies.

The platform is intended for healthcare teams responsible for peritoneal dialysis and home hemodialysis programs, as well as the patients participating in those programs. Availability will vary by region in line with local regulatory and operational requirements.

The launch of kinexus forms part of Fresenius Medical Care’s wider portfolio of products, services, and digital solutions for kidney care across different treatment settings. By bringing existing home dialysis digital capabilities into a broader global platform, the company aims to strengthen the role of connected technology in supporting high-quality, patient-centered care for people dialyzing at home.

Fresenius Medical Care is presenting kinexus at the European Renal Association Congress 2026, taking place from June 3 to 6 in Glasgow, Scotland.

Huma Therapeutics Limited is the digital health platform partner and legal manufacturer of kinexus, while Fresenius Medical Care Deutschland GmbH serves as the authorized distributor.

Fresenius Medical Care is a global provider of products and services for people with renal diseases. Around 4.5 million patients worldwide regularly undergo dialysis treatment, and the company provides dialysis care for approximately 290,000 patients through a network of 3,539 clinics. Fresenius Medical Care also supplies dialysis products, including dialysis machines and dialyzers. The company is listed on the Frankfurt Stock Exchange under FME and on the New York Stock Exchange under FMS.

About Fresenius Medical Care:

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Huma Therapeutics Limited is the digital health platform partner and legal manufacturer of kinexus. Fresenius Medical Care Deutschland GmbH acts as the authorized distributor.

For more information about Huma Therapeutics Limited visit the company’s website at www.huma.com

Media contact:

Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com

Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com

Contact for analysts and investors:

Dr. Dominik Heger
T +49 6172 609 2525
Dominik.Heger@FreseniusMedicalCare.com
www.freseniusmedicalcare.com 

SOURCE: Fresenius Medical Care AG